Abstract
Introduction. Neuropsychiatric symptoms (NPS) are common in mild cognitive impairment (MCI) but its role as a predictive factor for the progression to dementia is still not clear. The objective of this study is to identify NPS that predict the progression from amnestic MCI (a-MCI) to dementia using an easy to administer screening tool for NPS. Material and Methods. 132 patients with a-MCI were assessed for NPS by the Neuropsychiatric Inventory (NPI) and followed to detect progression to dementia. Results. The mean follow-up time was 3.5±2.9 years and rate of progression to dementia 28.8%. Two items of NPI were found to be independent risk factors for progression, nighttime behavioural disturbance (hazard ratio(HR)=2.2, 95%CI=1.10-4.43), anxiety (HR=2.5, 95%CI=1.01-6.20) and apathy (HR=2.2, 95%CI=1.003-4.820). The risk of progression increased with higher score on NPI (HR=1.046 per point, 95%CI=1.019- 1.073), and with a higher number of items of NPI affected (HR=3.6 per item, 95%CI=2.0-6.4). Faster progression to dementia was observed in patients with either nighttime behavioural disturbance, apathy or anxiety (4.6 vs. 8.3 years, 5.3 vs. 8.4 years and 3.0 vs. 7.7 years respectively, p<0.01) as well as in those with a higher number of items affected (no items = 9.2 years, 1-3 items = 6.6 years and >3 items = 2.9 years, p<0.001). Conclusions. Assessing a broad spectrum of NPS can help identify patients with a-MCI presenting a higher risk for progression to dementia. This can be useful to select patients for closer follow-up, clinical trials and future therapeutic interventions.
Keywords: Alzheimer’s disease, anxiety, apathy, dementia, mild cognitive impairment, neuropsychiatric inventory, neuropsychiatric symptoms, progression
Current Alzheimer Research
Title:Neuropsychiatric Symptoms in Amnestic Mild Cognitive Impairment: Increased Risk and Faster Progression to Dementia
Volume: 10 Issue: 1
Author(s): Johanne Somme, Manuel Fernandez-Martínez, Ana Molano and Juan Jose Zarranz
Affiliation:
Keywords: Alzheimer’s disease, anxiety, apathy, dementia, mild cognitive impairment, neuropsychiatric inventory, neuropsychiatric symptoms, progression
Abstract: Introduction. Neuropsychiatric symptoms (NPS) are common in mild cognitive impairment (MCI) but its role as a predictive factor for the progression to dementia is still not clear. The objective of this study is to identify NPS that predict the progression from amnestic MCI (a-MCI) to dementia using an easy to administer screening tool for NPS. Material and Methods. 132 patients with a-MCI were assessed for NPS by the Neuropsychiatric Inventory (NPI) and followed to detect progression to dementia. Results. The mean follow-up time was 3.5±2.9 years and rate of progression to dementia 28.8%. Two items of NPI were found to be independent risk factors for progression, nighttime behavioural disturbance (hazard ratio(HR)=2.2, 95%CI=1.10-4.43), anxiety (HR=2.5, 95%CI=1.01-6.20) and apathy (HR=2.2, 95%CI=1.003-4.820). The risk of progression increased with higher score on NPI (HR=1.046 per point, 95%CI=1.019- 1.073), and with a higher number of items of NPI affected (HR=3.6 per item, 95%CI=2.0-6.4). Faster progression to dementia was observed in patients with either nighttime behavioural disturbance, apathy or anxiety (4.6 vs. 8.3 years, 5.3 vs. 8.4 years and 3.0 vs. 7.7 years respectively, p<0.01) as well as in those with a higher number of items affected (no items = 9.2 years, 1-3 items = 6.6 years and >3 items = 2.9 years, p<0.001). Conclusions. Assessing a broad spectrum of NPS can help identify patients with a-MCI presenting a higher risk for progression to dementia. This can be useful to select patients for closer follow-up, clinical trials and future therapeutic interventions.
Export Options
About this article
Cite this article as:
Somme Johanne, Fernandez-Martínez Manuel, Molano Ana and Jose Zarranz Juan, Neuropsychiatric Symptoms in Amnestic Mild Cognitive Impairment: Increased Risk and Faster Progression to Dementia, Current Alzheimer Research 2013; 10 (1) . https://dx.doi.org/10.2174/1567205011310010012
DOI https://dx.doi.org/10.2174/1567205011310010012 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Tyrosine Kinase Inhibitor as a new Therapy for Ischemic Stroke and other Neurologic Diseases: is there any Hope for a Better Outcome?
Current Neuropharmacology Epigenetic Mechanisms in Alzheimer's Disease
Current Medicinal Chemistry Disease Modifying Approaches for Alzheimers Pathology
Current Pharmaceutical Design Substance P and Alzheimer’s Disease: Emerging Novel Roles
Current Alzheimer Research NAD<sup>+</sup>/NADH Metabolism and NAD<sup>+</sup>-Dependent Enzymes in Cell Death and Ischemic Brain Injury: Current Advances and Therapeutic Implications
Current Medicinal Chemistry Nutritional Deficiency in Early Life Facilitates Aging-Associated Cognitive Decline
Current Alzheimer Research Which Drugs for the Control of Fever in Critical Patients
Current Drug Targets Stroke Suggests Increased Risk of Dementia
Current Alzheimer Research Biomarkers of Alzheimer's Disease Risk in Peripheral Tissues; Focus on Buccal Cells
Current Alzheimer Research Conformation as the Therapeutic Target for Neurodegenerative Diseases
Current Alzheimer Research Hybrid PET Imaging in Neurologic Disease: PET/MRI Rather than PET/CT
Current Medical Imaging Thrombolytic Treatment of Cardiac Myxoma-Induced Ischemic Stroke: A Review
Current Drug Safety Role of Granulocyte-colony Stimulating Factor in the Protection of Cerebral Vascular Endothelium, White Matter, and Cognition
Current Neurovascular Research Salidroside - Can it be a Multifunctional Drug?
Current Drug Metabolism Overactive Bladder - Current Treatment Modalities
Current Women`s Health Reviews Novel Target Sites for Drug Screening: A Special Reference to Cancer, Rheumatoid Arthritis and Parkinson’s Disease
Current Signal Transduction Therapy Salvia species, Interesting Plants Offering Perspectives in Alzheimer’s Disease
Current Traditional Medicine Microglia:Neuroprotective and Neurotrophic Cells in the Central Nervous System
Current Drug Targets - Cardiovascular & Hematological Disorders Emerging Risk Factors for Dementia: The Role of Blood Pressure Variability
CNS & Neurological Disorders - Drug Targets Biological Role of Formaldehyde, and Cycles Related to Methylation, Demethylation, and Formaldehyde Production
Mini-Reviews in Medicinal Chemistry